Imirestat

This classification denotes an aldose reductase inhibitor with the molecular formula C15H8F2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PM69S95UQ, chemically known as 2,7-difluorospiro(fluorene-9,4-imidazolidine)-2,5-dione but generally known as imirestat, which bears US NIH Compound Identifier 65673. European Medicines Agency schedules Imirestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08154MIG. The term IMIRESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). IMIRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imirestat under HS 29332100 and SITC 51572. As of Q4 2014, IMIRESTAT remains the US FDA Preferred Term for this commodity. Imirestat bears US NLM identifiers UMLS ID C0063406 and NCI Concept Code C96290. SMILES: FC1CC2C3(NC(=O)NC3=O)C3C(C2CC1)CCC(F)C3.